TNX-102 SL 2.8mg
TNX-CY-F202
Phase 3 small_molecule completed
Quick answer
TNX-102 SL 2.8mg for Primary Fibromyalgia is a Phase 3 program (small_molecule) at Tonix Pharmaceuticals Holding with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tonix Pharmaceuticals Holding
- Indication
- Primary Fibromyalgia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed